Insider

Thermo Fisher revenue rises 9% to $12.14 billion, earnings per share up 15%

Thermo Fisher's third-quarter revenue rose 9% to $12.14 billion from $11.12 billion a year earlier. Adjusted earnings per share increased 15% to $6.68.

Verified against 1 archived primary source · SHA-256 recorded Inspect sources & citations ↓
A laboratory workbench with a microscope and analytical equipment in a bright room
Photo by Trnava University on Unsplash
$12.14 billion
Quarterly revenue
$6.68
Adjusted EPS
9%
Revenue growth

Key points

  • Organic revenue, which excludes acquisitions, divestitures and currency effects, grew 6%.
  • Thermo Fisher completed the sale of its microbiology business.
  • The company said it would give its updated 2026 forecast during the investor conference call, so the release itself contains no forecast figures.

Profit grows faster than sales

Organic revenue, which excludes acquisitions, divestitures and currency effects, grew 6%. Earnings per share under reporting standards were $4.64, up 9%.

Operating income rose 17% to $2.26 billion, and operating margin widened to 18.6% from 17.4%. Adjusted operating margin reached 24.5% versus 23.3%.

Thermo Fisher revenue, third quarter

Q3 2025$11.12 billionQ3 2026$12.14 billion
Data from the original sources listed alongside.

Revenue by quarter, $B

11.4Q4 '24*17.7%10.4Q1 '2516.6%10.9Q2 '2516.9%11.1Q3 '2517.5%12.2Q4 '25*18.5%11Q1 '2616.9%12Q2 '2617.4%12.1Q3 '2618.6%
Bottom row: operating margin (operating income divided by revenue). Q4 = fiscal year minus the three quarters reported on their own. Revenue as the company tagged it in its SEC filings (XBRL). Guidance is the company's own, not our forecast.

Sector context: 36 covered companies in Health Care reported a median revenue change of +7.2% YoY in their latest filings.

What the company did in the quarter

Thermo Fisher completed the sale of its microbiology business. Together with Mayo Clinic, it launched Precure, an initiative that will combine data from more than one million patient samples with its protein analysis technologies.

Chief executive Marc Casper called it another excellent quarter and said the company is well positioned for a strong 2026.

What the report lacks

The company said it would give its updated 2026 forecast during the investor conference call, so the release itself contains no forecast figures.

What to check next

The fourth-quarter report will show whether organic growth continues and whether operating margin keeps widening.

Original sources

  1. 8-K EX-99.1 filing, October 21, 2026October 21, 2026SHA-256 of our archived copy 6f04c0df35a0…
Cite this article

The fingerprint identifies the exact version of each original that the article was written from; the original stays at its source.

Prepared by AI from official company documents; automatic checks and an AI editor review it before publication, and not every article is read by a person. This is not investment advice. Editorial standards